Alexey Berezhnoy
Director, Immunology Zymeworks
Seminars
Wednesday 10th September 2025
ZW1528: A Dual-Targeting Bispecific Antibody to Broadly Suppress Airway Inflammation by Inhibiting IL-4Ra and IL-33 Pathways
1:00 pm
- Exploring how ZW1528 binds to both IL-4Ra and IL-33, and mediates potent blockade of IL-4, IL-13 and IL-33 enabling a broad and simultaneous inhibition of key inflammatory pathways
- Demonstrating translational relevance as ZW1528 inhibits Type 2 and non-Type 2 responses in vitro in primary immune cells of COPD patients, effectively modulating diverse immune pathways across patient subtypes
- Investigating how ZW1528 demonstrates IgG-like PK and biomarkers of target blockade in the NHP, supporting clinical viability through favourable pharmacokinetics and validated target engagement
